MRI reveals when cognitive impairment will advance
Swiss researchers used susceptibility-weighted MRI and an artificial intelligence technique to help identify which individuals with mild cognitive impairment will continue to decline.
Swiss researchers used susceptibility-weighted MRI and an artificial intelligence technique to help identify which individuals with mild cognitive impairment will continue to decline.
Susceptibility-weighted MRI measures magnetic susceptibility phase-effect differences between tissues. Using the technique, researchers were able to view details of the blood vessels in the brain, including microhemorrhages and microbleeds.
The scans revealed microbleeds in 33% subjects with stable mild cognitive impairment. They found microbleeds in 54% of those with progressive cognitive impairment and in 14% of the control group. The study appeared in Radiology.
The researchers also analyzed the data with support vector technology algorithms to identify patterns within a group and create classifications. By adding the support vector technology to the baseline MRI data the researchers were able to distinguish patients with mild cognitive impairment with 85% accuracy.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
